Affiliation:
1. Boston University School of Medicine & Boston Medical Center, Boston, MA 02118, USA
Abstract
Contrave® is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification. Its safety and efficacy were assessed in four randomized, double-blind, placebo-controlled, 56-week Phase III clinical trials in 4536 adult subjects: COR-1, COR-II, COR-BMOD and COR-DM. All four studies demonstrated statistically significant and clinically meaningful weight loss following up to 52 weeks of treatment with naltrexone/bupropion compared with placebo. The average weight loss from baseline across the four studies was approximately 11–22 lbs (5–9 kg). Results show the efficacy of Contrave for weight loss, as well as significant improvements in cardiometabolic markers. This review focuses on the four studies, their outcomes and the mechanism of action of Contrave.
Subject
Cardiology and Cardiovascular Medicine,Molecular Medicine
Reference38 articles.
1. National Heart Lung, and Blood Institute, U.S. Department of Health and Human Services. What causes overweight and obesity? (2012). www.nhlbi.nih.gov/health/health-topics/topics/obe/causes#
2. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
3. Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
4. Ogden CL, Carroll MD. Prevalence of overweight, obesity, and extreme obesity among adults: United States, trends 1960–1962 through 2007–2008, NCHS Health E-Stat, Hyattsville, MD: National Center for Health Statistics (2010). www.cdc.gov/nchs/data/hestat/obesity_adult_07_08/obesity_adult_07_08.pdf.
5. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献